BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...that have gone public in Hong Kong this year, such as Akeso Inc. (HKEX:9926) and Kintor Pharmaceuticals Ltd....
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

...$240 million) through the sale of 92.3 million shares at HK$20.15. The oversubscribed offering valued Kintor Pharmaceuticals Ltd....
...for lead androgen receptor antagonist proxalutamide (GT0918) to treat metastatic castration-resistant prostate cancer Paul Bonanos, Associate Editor Kintor Pharmaceuticals Ltd. IPO...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...process is complete.” There are at least six biotechs in the HKEX IPO queue, and Kintor Pharmaceuticals Ltd....
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...HKEX:1873), QureBio is developing bispecifics to treat cancer. Kintor sets terms for Hong Kong IPO Kintor Pharmaceuticals Ltd....
...T cell or vaccine based therapies. Elizabeth S. Eaton and Hongjiang Li, Staff Writers JNJ-68284528, JNJ-4528 (LCAR-B38M) Proxalutamide (GT0918) Kintor Pharmaceuticals Ltd. MyoKardia...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...therapy company’s seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. Kintor Pharmaceuticals Ltd. TwinStrand IPO...
BioCentury | Aug 22, 2019
Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

...CMAB to manufacture Kintor’s ACVRL1 antibody CDMO company CMAB Biopharma Inc. (Suzhou, China) partnered with Suzhou Kintor Pharmaceuticals...
...Academy of Sciences CMAB Biopharma FibroGen Inc. GlaxoSmithKline plc Haihe Biopharma Co. Ltd. Jinan University Massachusetts General Hospital Pfizer Inc. Tonix Pharmaceuticals Holding Corp. Kintor Pharmaceuticals Ltd. Activin...
BioCentury | Mar 30, 2018
Company News

Management tracks: Pacira, Suzhou Kintor

...Scott Braunstein has left the company. CEO David Stack will assume his duties. Cancer company Suzhou Kintor Pharmaceuticals...
BioCentury | Feb 2, 2018
Company News

Pfizer, Kintor in deal for ACVRL1 mab

...Pfizer Inc. (NYSE:PFE) granted Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) exclusive, worldwide rights to develop and commercialize PF-03446962...
...to inquiries. Pfizer Inc. (NYSE:PFE), New York, N.Y. Suzhou Kintor Pharmaceuticals Inc., Suzhou, China Business: Cancer Chris Lieu PF-03446962 PF-3446962 Pfizer Inc. Kintor Pharmaceuticals Ltd. Activin...
Items per page:
1 - 10 of 12
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...that have gone public in Hong Kong this year, such as Akeso Inc. (HKEX:9926) and Kintor Pharmaceuticals Ltd....
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

...$240 million) through the sale of 92.3 million shares at HK$20.15. The oversubscribed offering valued Kintor Pharmaceuticals Ltd....
...for lead androgen receptor antagonist proxalutamide (GT0918) to treat metastatic castration-resistant prostate cancer Paul Bonanos, Associate Editor Kintor Pharmaceuticals Ltd. IPO...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...process is complete.” There are at least six biotechs in the HKEX IPO queue, and Kintor Pharmaceuticals Ltd....
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...HKEX:1873), QureBio is developing bispecifics to treat cancer. Kintor sets terms for Hong Kong IPO Kintor Pharmaceuticals Ltd....
...T cell or vaccine based therapies. Elizabeth S. Eaton and Hongjiang Li, Staff Writers JNJ-68284528, JNJ-4528 (LCAR-B38M) Proxalutamide (GT0918) Kintor Pharmaceuticals Ltd. MyoKardia...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...therapy company’s seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. Kintor Pharmaceuticals Ltd. TwinStrand IPO...
BioCentury | Aug 22, 2019
Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

...CMAB to manufacture Kintor’s ACVRL1 antibody CDMO company CMAB Biopharma Inc. (Suzhou, China) partnered with Suzhou Kintor Pharmaceuticals...
...Academy of Sciences CMAB Biopharma FibroGen Inc. GlaxoSmithKline plc Haihe Biopharma Co. Ltd. Jinan University Massachusetts General Hospital Pfizer Inc. Tonix Pharmaceuticals Holding Corp. Kintor Pharmaceuticals Ltd. Activin...
BioCentury | Mar 30, 2018
Company News

Management tracks: Pacira, Suzhou Kintor

...Scott Braunstein has left the company. CEO David Stack will assume his duties. Cancer company Suzhou Kintor Pharmaceuticals...
BioCentury | Feb 2, 2018
Company News

Pfizer, Kintor in deal for ACVRL1 mab

...Pfizer Inc. (NYSE:PFE) granted Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) exclusive, worldwide rights to develop and commercialize PF-03446962...
...to inquiries. Pfizer Inc. (NYSE:PFE), New York, N.Y. Suzhou Kintor Pharmaceuticals Inc., Suzhou, China Business: Cancer Chris Lieu PF-03446962 PF-3446962 Pfizer Inc. Kintor Pharmaceuticals Ltd. Activin...
Items per page:
1 - 10 of 12